Clinical Trial Update: LM103 in Phase IIa Clinical Trial for Adjuvant Treatment in Patients With Non-small Cell Lung Cancer [Phase 2]

View source ↗

Summary

A Phase IIa adjuvant trial of LM103 for non-small cell lung cancer is listed as not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• LM103

Snippet

Sponsor: Suzhou BlueHorse Therapeutics Co., Ltd. | Conditions: Non-Small Cell Lung Cancer | Phase 2 | Status: NOT_YET_RECRUITING